WASHINGTON, APRIL 17, 2026 —
Key Takeaways
- The American Heart Association and American College of Cardiology released landmark new heart disease prevention guidelines in March 2026 — the first full update since 2018 — calling for cholesterol screening to begin at age 30 and treatment to start far earlier than current practice.
- A new blood test called Lp(a) — a cholesterol particle strongly linked to inherited heart disease risk — is now recommended as a one-time test for every adult in America, yet the vast majority of Americans have never heard of it or been tested.
- The new guidelines cut the treatment threshold for LDL cholesterol nearly in half for high-risk patients, setting a target of 55 mg/dL for those at very high risk — a number many patients currently managing “normal” cholesterol are far above.
Heart disease kills more Americans than any other condition — more than all cancers combined. More than 800,000 Americans die from cardiovascular disease each year. And according to cardiologists who helped write the sweeping new 2026 guidelines, the vast majority of those deaths are preventable — if the right people are identified early enough and treated aggressively enough before damage to their arteries becomes irreversible.
The problem has been that the United States has been identifying the wrong people at the wrong time, using outdated tools and conservative treatment thresholds that leave millions at high risk walking out of their doctor’s office believing they are fine.
The 2026 guidelines — issued jointly by the American Heart Association, the American College of Cardiology, and nine other major medical organizations — represent the most significant overhaul of cardiovascular prevention guidance in nearly a decade. For millions of Americans, they change the conversation about what normal cholesterol means, who should be on medication, and how young prevention should start.
Why Risk Assessment Now Starts at 30
The most striking change in the new guidelines is the drop in the recommended age for formal cardiovascular risk assessment from 40 to 30 years old.
The science behind this shift is straightforward. Atherosclerosis — the buildup of fatty plaque inside arteries that eventually causes heart attacks and strokes — does not begin in middle age. It begins in early adulthood and progresses silently for decades. Autopsy studies of young men killed in military service have found early plaque in arteries of people in their 20s. The damage accumulates slowly, often invisibly, for 20 to 30 years before it produces a first heart attack.
The guidelines now call for using a newly validated risk calculator called PREVENT — built from the health records of more than 3 million contemporary Americans — to estimate both 10-year and 30-year cardiovascular risk beginning at age 30. The old calculator had been shown to overestimate risk by 40% to 50% in many patients, leading to overtreating some people and undertreating others. The new calculator also incorporates factors the old one missed entirely — kidney function, inflammation markers, and metabolic health — producing a far more accurate individual risk profile.
The practical implication: a 35-year-old with elevated LDL cholesterol and a family history of early heart disease should now be discussing statin therapy with their doctor. Under prior guidelines, that same conversation would have waited until age 40 or later.
The LDL Targets That Should Be on Every American’s Refrigerator
For the first time in eight years, the guidelines restore specific numerical LDL cholesterol targets — moving away from the vague “lower is better” language of the 2018 recommendations that left patients and doctors without clear goalposts.
| Risk Category | LDL Target | Who This Applies To |
|---|---|---|
| Very high risk | Under 55 mg/dL | Known heart disease, prior stroke, multiple high-risk conditions |
| High risk | Under 70 mg/dL | Diabetes + cardiovascular risk, intermediate+ 10-year risk |
| Primary prevention (no disease) | Under 100 mg/dL | General adult population without established CVD |
| Borderline risk (3–5% 10-year) | Lifestyle first, medication considered | Younger adults with elevated risk factors |
The 55 mg/dL target for very high-risk patients represents one of the most aggressive cholesterol standards in the world — and reflects a decade of clinical trial data showing that lower LDL produces fewer heart attacks and strokes, with no floor below which additional benefit disappears.
Achieving 55 mg/dL is not possible for many patients with statins alone. The guidelines now explicitly endorse the combination of statins with newer medications — including PCSK9 inhibitors, bempedoic acid, and inclisiran — to achieve targets that were previously unreachable with older treatments. This expanded toolkit means patients who have tried statins and “couldn’t get their cholesterol down enough” now have additional options that their doctor may not have yet discussed with them.
The Blood Test Almost No One Has Had — But Everyone Should
The most significant new recommendation that most Americans will never have heard of is the formal call for universal Lp(a) testing — at least once in every adult’s lifetime, regardless of other cholesterol levels.
Lipoprotein(a) — pronounced “el-pee-little-a” — is a cholesterol particle that carries an additional protein called apolipoprotein(a), giving it a stickiness that makes it particularly prone to lodging in artery walls and contributing to plaque. Unlike LDL, which is significantly influenced by diet and lifestyle, Lp(a) is almost entirely genetically determined. It does not meaningfully respond to statins or exercise or dietary changes.
Elevated Lp(a) is present in roughly 20% of the population — approximately 64 million Americans — and increases heart disease risk by 40% to 90% depending on the level. It is one of the most common inherited causes of premature heart attack. Yet the vast majority of Americans who carry high Lp(a) have never been tested, because the test was not part of standard cardiovascular screening and most doctors did not order it routinely.
The new guidelines make the test a formal recommendation for all adults. A single lifetime measurement is sufficient for most people because Lp(a) levels remain stable throughout adulthood. If your level is elevated, your doctor can factor it into your overall risk assessment and be more aggressive with other risk factors — LDL, blood pressure, inflammation — that are modifiable.
Children Need Cholesterol Screening Too — Starting at Age 9
In a recommendation that surprised many patients, the guidelines call for universal lipid screening for all children between the ages of 9 and 11 — and earlier screening starting at age 2 for children with a family history of premature heart disease or inherited cholesterol disorders.
The rationale is the hereditary condition called familial hypercholesterolemia, or FH — an inherited genetic disorder that causes dramatically elevated LDL from birth. FH affects approximately 1 in 250 to 300 people — meaning roughly 1.3 million Americans carry it. Without treatment, people with FH have a 2 to 4 times higher risk of heart attack at young ages, with up to 20% of adults presenting with a premature heart attack found to have undiagnosed FH. Despite this, as many as 90% of people with FH have never been diagnosed.
A simple childhood lipid screening catches these children early enough to begin treatment in their teens — treatment that dramatically reduces the lifetime burden of arterial plaque accumulation and prevents premature heart attacks in their 30s, 40s, and 50s.
Pro Tips a Generic Article Would Miss
1. Get your Lp(a) tested this year. If your doctor has not discussed this test with you, ask for it specifically. The 2026 guidelines now make this a formal recommendation, but it will take months for clinical practice to catch up to the guideline. A single blood draw measures it. If your level is elevated — particularly above 125 nmol/L — it should change how aggressively you and your doctor manage your other modifiable risk factors.
2. The new risk calculator may change whether you qualify for a statin. The old ASCVD risk calculator significantly overestimated risk for many patients. If you were previously told you were “high risk” and started a statin based on the old calculator, it is worth asking your doctor to re-run your risk using the new PREVENT equations. Some patients who were overtreated may be appropriate for lower-intensity therapy. Others who were undertreated may finally get the level of treatment their actual risk warrants.
3. If you have had a pregnancy complication, your heart risk is higher than standard calculators show. The 2026 guidelines formally incorporate pregnancy-related risk factors — preeclampsia, gestational diabetes, premature delivery — as risk enhancers that should trigger earlier and more aggressive screening. Women who experienced these conditions are at meaningfully higher lifetime cardiovascular risk than women without them, a fact that has historically been underappreciated in clinical practice.
Actionable Step
At your next physical, ask your doctor to run a full lipid panel that includes LDL, HDL, triglycerides, and — for the first time — Lp(a). Ask them to use the AHA’s new PREVENT calculator to estimate your 10-year and 30-year cardiovascular risk. If you are between 30 and 40 with any elevated risk factors — family history, elevated LDL, high blood pressure, diabetes, or obesity — ask whether the new 2026 guidelines change the recommended treatment approach for your specific situation. And if you have children between 9 and 11 who have never had a cholesterol check, schedule one.
